Aquyre Biosciences Announces Appointment of F. Samuel Eberts III as CEO and Chairman of the Board of Directors & Founder Bertrand de Poly as Chief Strategy & Technology Officer
3.5.2023 20:04:00 EEST | Business Wire | Press release
Aquyre Biosciences, Inc. today announced the appointment of F. Samuel Eberts III as Chief Executive Officer and Chairman of its Board of Directors. Founder Bertrand de Poly will assume the role of Chief Strategy & Technology Officer, focusing on strategy and technological development, along with his continued service on the board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230503005760/en/
F. Samuel Eberts III, Chief Executive Officer and Chairman of the Board of Directors (Photo: Business Wire)
This evolution in management aims to take the company to its next stage of growth, building on recent achievements including the acceptance of a clinical study manuscript with Johnson & Johnson at Boston University and Fox Chase Cancer Center, to be presented at the American Thoracic Society meeting in Washington, DC on May 19-24, 2023.
Samuel Eberts brings to Aquyre Biosciences decades of experience at the intersection of healthcare, law, and academia. His varied career includes equity partnership and board, and investment committee membership at a private equity firm whose collaboration with Harvard-affiliated Mass General’s Wellman Center facilitated world-class medical insights, and ongoing engagements as a Partner at Market Street HealthCare Partners, a private equity sponsor for healthcare investments. For 15 years, Sam was part of the senior management team at LabCorp, where he served as Chief Legal Officer, Corporate Secretary, and Senior Vice President of Corporate Affairs, with oversight of regulatory, government relations, and merger and acquisition activities. He is a senior advisor for healthcare investments to Aquyre’s shareholder, Invescore. Sam is also a Senior Lecturing Fellow at Duke University School of Law, a member of the advisory board for the Wilson Center, and has served on the World Policy Institute Advisory Board, the Harvard Law School Corporate Governance Forum, and the John F. Kennedy School of Government Healthcare Policy Leadership Council. He also serves on the board of several non-profit organizations.
“I am delighted that Samuel has agreed to help take Aquyre to the next level of its growth journey as we further refine our technology and scale our partner solutions and corporate operations. I look forward to working with him to help ensure the success of our company,” said Bertrand de Poly.
“I am particularly pleased that among the many shareholders of Aquyre, Canon Medical Systems Corporation, the medical equipment subsidiary of the optical, imaging, and industrial multinational Canon, Inc., is a strategic investor,” said Samuel Eberts. “I am honored to be leading such an impressive collection of people and products and am excited about the potential of Aquyre Biosciences. It is humbling and exciting to be part of an organization that will play an important role in healthcare. We are well positioned to bring a new level of precision in diagnosis of cancer, improving the lives of patients.”
About Aquyre Biosciences
Aquyre Biosciences, Inc is the creator of CelTivity™, the industry leader in two-minute lung biopsy adequacy assessment. Powered by two proprietary technologies including Dynamic Cell Imaging™ (DCI), CelTivity can scan a biopsy and measure intracellular and metabolic activity throughout extracted tissue. This activity is presented in a heatmap, making it easy to interpret. The assessment does not require any cutting or staining, meaning the same tissue assessed for adequacy can go to final pathology to review for cancer, granuloma, lymphocytes, and more. Aquyre Biosciences is headquartered out of Weston, Mass. For more information, please visit www.aquyre.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230503005760/en/
Contact information
Emily Ritacco
Director of Marketing
eritacco@aquyre.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Brings Direct-to-Consumer Commerce Expertise to Gamesforum Hamburg 2026 With Keynote and Panel Appearances9.6.2026 15:01:00 EEST | Press release
Xsolla, a global leader in video game commerce, today announced its participation in Gamesforum Hamburg 2026, taking place June 9–10, 2026, at NORD EVENT Panoramadeck in Hamburg, Germany. As an Exclusive Global Partner of the Gamesforum series, Xsolla will bring its direct-to-consumer commerce expertise to one of Europe's leading gatherings for mobile game growth and monetization, with Jane Startseva, Vice President of Business Development, EMEA, taking the stage across two sessions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609166526/en/ Graphic: Xsolla Xsolla's presence in Hamburg underscores its role at the center of gaming's shift toward direct-to-consumer commerce: On June 9 at 10:00 AM, Jane joined Adam Smart, Global Director of Product – Gaming at AppsFlyer, for a 30-minute keynote titled "Web Shops and Attribution: Closing the Revenue Gap." As web shops cement their role as a primary monetization channel for
Duetti Expands Funding Offerings for Independent Artists With Two New Programs9.6.2026 15:01:00 EEST | Press release
Duetti Inc. (“Duetti” or the “Company”), the music company that partners with independent artists and songwriters to buy, manage, and market their catalogs, announces today a significant expansion of its funding offering. Artists can now sell their master recording tracks, or parts thereof, in as little as six months after release - substantially earlier than the company’s prior two-year threshold. Duetti is also launching its new Remix Program, which allows independent artists to create remixes, covers, and other derivative works from Duetti’s 30,000-track catalog (across both masters and compositions). In return, artists can receive upfront cash compensation, ongoing royalty % share, 0% distribution fees, and dedicated marketing support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609063445/en/ UNLOCKING VALUE, EARLIER THAN EVER Duetti is leveraging its proprietary AI-driven predictive models to materially lower the
The Open Group Releases OSDU® Data Platform Standard, Version 1.09.6.2026 15:00:00 EEST | Press release
The Open Group, the global vendor‑neutral technology consortium, today announced the release of the OSDU® Data Platform Standard, Version 1.0. The new standard establishes a stable, clearly defined baseline for data platform capabilities, supporting greater interoperability, consistency, and confidence across the energy industry. The OSDU Data Platform Standard, Version 1.0 is designed to help organizations better manage, access, and use enterprise data by reducing fragmentation and breaking down data silos. It provides a common framework for organizing and accessing data securely and efficiently, supporting improved collaboration, innovation, and decision‑making. Key benefits of the standard include interoperability by design, increased stability for application development and deployment, and a clear foundation for certification. Operators benefit from greater choice and reduced integration effort, independent software vendors can develop against a defined standard, and platform prov
Clearlake Completes Strategic Acquisition of Pathway Capital Management9.6.2026 15:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced the completion of its acquisition of Pathway Capital Management (“Pathway”), a global provider of private market solutions for institutional and wealth markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609839186/en/ The strategic acquisition significantly expands Clearlake’s private markets platform, adding complementary capabilities and reinforcing its position as a leading diversified alternative asset manager. Founded in 1991, Pathway manages more than $95 billion in assets and brings a proven track record across private equity, private credit, infrastructure, secondaries and co-investments through customized private markets programs and multi-investor funds. The combination will bolster Clearlake’s priva
Watchmaker to Unveil New Technologies Addressing NGS Workflow Bottlenecks and Sequencing Accuracy Challenges at ESHG 20269.6.2026 15:00:00 EEST | Press release
Watchmaker Genomics, a leader in high-performance NGS workflow solutions, today announced it will unveil two new technologies at the European Society of Human Genetics (ESHG) 2026 conference, designed to address persistent bottlenecks in sequencing workflow scalability and amplification accuracy. The launches include the EquiPlex™ Normalization Kit, which simplifies library normalization using a novel Cas9-based approach, and Equinox® Prime Library Amplification Master Mix, engineered to improve indel accuracy in repetitive genomic regions while delivering superior amplification performance across sequencing applications. Built on Watchmaker’s expertise in protein engineering and integrated workflow design, the technologies reflect the company’s continued focus on solving real-world sequencing challenges that impact operational efficiency, scalability, and downstream data quality. “Sequencing workflows continue to grow in scale and complexity, but many of the core bottlenecks researche
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom